Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatomas Therapy
Reports outline hepatomas therapy research from P. García-Maceira and colleagues
February 24th, 2009
Investigators publish new data in the report 'Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.' "The hypoxia-inducible factor 1 (HIF-1) plays a critical role for tumor adaptation to microenvironmental hypoxia, and represents an appealing chemotherapeutic target. Silibinin is a nontoxic flavonoid reported to exhibit anticancer properties," researchers in Madrid, Spain report. "However, the mechanisms by which silibinin inhibits tumor growth are not fully understood. In this study, silibinin was found to inhibit hypoxia-induced HIF-1alpha...
Source: Cancer Weekly (2009-02-24)
|
